MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2026-03-31.

Income Overview

Net Income
-$2,733K
EPS
$0.85
Unit: Thousand (K) dollars

Income Statement
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Research And Development
1,370 2,377* 2,157 1,018
General And Administrative
1,379 891* 1,135 1,266
Total operating expenses
2,749 3,267 3,292 2,284
Operating loss
--3,267* -3,292 -2,284
Financial expenses
-16 -2* -30 216
Loss before income tax
-2,733 -3,265* -3,262 -2,500
Income tax
--1* 0 3
Net loss
-2,733 -3,264 -3,262 -2,503
Basic EPS
0.85 -2.455 2.88 4.32
Diluted EPS
0.85 -2.455 2.88 4.32
Basic Average Shares
3,230,378 1,329,515* 1,132,658 579,523
Diluted Average Shares
3,230,378 1,329,515* 1,132,658 579,523
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

DownloadDownload image
Net loss-$2,733K Loss before incometax-$2,733K Financial expenses-$16K Total operatingexpenses$2,749K General AndAdministrative$1,379K Research And Development$1,370K

Silexion Therapeutics Corp (SLXNW)

Silexion Therapeutics Corp (SLXNW)